Business Context and Reporting Period
Company: Spero Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 17, 2026
Reporting Period: Event-based report regarding FDA approval received on June 17, 2026.
Key Financial Metrics
This filing is a current report regarding a regulatory milestone and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Regulatory Approval: The U.S. Food and Drug Administration (FDA) granted approval for Utebzi (tebipenem pivoxil), an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis.
- Market Position: Utebzi is the first and only oral carbapenem antibiotic approved for adult patients with limited or no alternative oral treatment options.
- Timing: Approval was received one day in advance of the FDA-assigned Prescription Drug User Fee Act (PDUFA) date of June 18, 2026.
Outlook, Management Commentary, and Risks
- Commercialization: The approval results from GlaxoSmithKline's (GSK) development and an exclusive global licensing agreement with Spero Therapeutics (excluding select Asian territories).
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.
- Risks: No specific risks or contingencies are detailed in the body of this 8-K; the press release (Exhibit 99.1) would contain further details on commercialization risks.
Investor Verification Checklist
- Verify the terms of the exclusive global licensing agreement with GSK, specifically regarding royalty rates and milestone payments.
- Review the full text of the press release (Exhibit 99.1) for specific indications, contraindications, and limitations of the Utebzi approval.
- Confirm the commercial launch timeline and GSK's marketing strategy for the product.
- Check subsequent filings for any financial impact of the approval on Spero's cash position or revenue recognition.